Statement: Patients in the primary trial and the secondary trial did not have any of the same adverse events.
Primary_evidence: Adverse Events 1:   Total: 6/25 (24.00%)   Supraventricular extrasystoles 1/25 (4.00%)   Ventricular extrasystoles 1/25 (4.00%)   Ascites 2/25 (8.00%)   Diarrhea 1/25 (4.00%)   Nausea 1/25 (4.00%)   Pancreatitis 1/25 (4.00%)   Small intestinal obstruction 1/25 (4.00%)   Vomiting 1/25 (4.00%)   Bile duct obstruction 1/25 (4.00%)   Portal hypertension 1/25 (4.00%)
Secondary_evidence: Adverse Events 1:   Total: 6/19 (31.58%)   Febrile neutropenia  [1]1/19 (5.26%)   Fatigue  [1]1/19 (5.26%)   Pyrexia  [1]1/19 (5.26%)   Fracture  [1]1/19 (5.26%)   Hip Fracture  [1]1/19 (5.26%)   Headache  [2]1/19 (5.26%)